"For too long, schools and colleges have been forced to patch and mend buildings that have already deteriorated - spending their time worrying about leaking roofs instead of focusing on what matters most: giving every child the best possible education," she said.
"For too long, schools and colleges have been forced to patch and mend buildings that have already deteriorated - spending their time worrying about leaking roofs instead of focusing on what matters most: giving every child the best possible education," she said.
Earnings Call Insights: Insperity (NSP) Q4 2025 Management View CEO Paul Sarvadi discussed decisive actions taken in Q4 to address challenges from 2025, focusing on stability and long-term value creation. He stated that "the highlight of the fourth quarter was the achievement of our #1 priority to finish our fall sales and retention campaign with measurable margin recovery. We accomplished this ke...
Earnings Call Insights: Insperity (NSP) Q4 2025 Management View CEO Paul Sarvadi discussed decisive actions taken in Q4 to address challenges from 2025, focusing on stability and long-term value creation. He stated that "the highlight of the fourth quarter was the achievement of our #1 priority to finish our fall sales and retention campaign with measurable margin recovery. We accomplished this key objective." Sarvadi highlighted the launch of a three-year plan aimed at margin recovery in 2026, balanced growth in year two, and high-performance metrics in year three. He reported that new booked HR360 sales for the year were within 2% of the prior year despite a 14% reduction in Business Performance Advisors and a 13% improvement in sales efficiency. Sarvadi explained that the rollout of HRScale, a joint solution with Workday targeting mid-market companies, is "one of the most significant transformations that has occurred at Insperity," and is expected to drive growth and retention. He noted that pipeline activity is strong with 6,000 to 8,000 paid worksite employees expected on HRScale by year-end 2026. Sarvadi announced a realignment impacting approximately 4% of non-sales staff to strengthen the business and position for future growth. He described this as "a difficult but necessary decision to rightsize our organization to the current and future needs of the company." CFO James Allison reported, "Today, we reported adjusted EPS for the fourth quarter of minus $0.60 and adjusted EBITDA of minus $13 million." He detailed that Q4 included $2.8 million in accelerated sales office consolidation expenses and investments of $15 million in HRScale. Allison also discussed the amended credit facility, which increased borrowing capacity to $750 million and raised the maximum leverage ratio. Outlook Allison forecasted average paid worksite employees for Q1 2026 in the range of 303,000 to 305,000 and for the full year in a range from minus 1.5% to plus 1.5% growth. He stated, ...
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its previously announced underwritten public offering of shares of its common stock. Galecto is selling a total of 14,473,685 shares of common stock at a p...
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its previously announced underwritten public offering of shares of its common stock. Galecto is selling a total of 14,473,685 shares of common stock at a public offering price of $19.00 per share. In addition, Galecto has granted the underwriters a 30-day option to purchase an additional 2,171,052 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Galecto from the offering are expected to be approximately $275 million, before deducting underwriting discounts and commissions and offering expenses payable by Galecto and assuming no exercise of the underwriters’ option to purchase additional shares. All of the securities are being offered by Galecto. The offering is expected to close on or about February 12, 2026, subject to customary closing conditions. Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering. An automatically effective shelf registration statement relating to these securities was filed with the Securities and Exchange Commission (SEC) on February 10, 2026. This offering is being made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. A copy of the final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov and, when available, may be obtained from: Jefferies LLC (Attention: Equity Syndicate Prospectus Departmen...